Bringing Particle Analysis to Earlier Stages of Drug Development

Leverage the game-changing power of Aura to achieve comprehensive particle analysis at earlier stages in biotherapeutic development—a critical quality attribute (CQA) for safety and efficacy.


Don’t Let Subvisible Particles Threaten Your Drug’s Efficacy

Subvisible particles, measuring roughly 10 µm in size, can cause a range of serious health issues, from clogging capillaries to sparking life-threatening immune reactions. In response to the alarming effects these particles pose, the FDA has set strict standards for injectable drug products: they must be virtually free of them.

Manufacturers need powerful technology solutions capable of fully characterizing subvisible particles throughout the development cycle to ensure therapies are safe and effective prior to patient use.

Yet legacy particle analysis methods fail to provide adequate protection, leaving invisible particles unchecked and patient safety in danger.

What if there was a more efficient solution?

Develop Faster, Smarter, Safer When You Rethink Particle Analysis

Why Use Aura for Particle Analysis?

  • Detect and characterize particles not measured by dynamic light scattering (DLS) or size exclusion chromatography (SEC)
  • Preserve sample, using as little as 5 μL per test
  • Screen a wide range of conditions with our 96-well format
  • Obtain detailed information on particles that other methods can’t deliver, including size, morphology, count, and distribution
  • Move quickly with an analysis time of about 1 minute per sample
  • Evaluate a wide range of particle sizes, measuring 1 μm to 5 mm with high reproducibility
  • Achieve high sensitivity because particles are imaged without the interference of buffer or matrix
  • See more detail for better particle identification with high-resolution magnification
  • Maintain compliance with the option for 21 CFR Part 11 software

Small Volumes, Fast Answers

With Aura, you only need a small volume of material to get answers quickly, so you don’t waste time or money on products that won’t make it through development.

When you can assess visible and subvisible particles using microliter volumes at high throughput AND identify particles through fluorescence methods, you get a powerful screening tool that speeds up development from pre-IND into clinical phases.

USP 788 Compliant Data